PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the House Committee on Energy and Commerce.
Congressional Research Service
No official summary is available in the imported record yet.
People & committees
Rep. Morelle, Joseph D. [D-NY-25] · D–NY
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We also preserved the text version used in the PlainBill explanation below.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Sep 24, 2026. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.1806 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.1806 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.1806 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.1806 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.
PlainBill explanation
Based on the full Introduced in House · 2025-03-03 text. This explanation has not received human editorial review. This overview describes the proposal’s major provisions; it does not establish what its real-world effects would be.
This bill would expand federal research on triple-negative breast cancer and require federal agencies to share information with the public and health care providers. Education would cover treatment options and the elevated risk for minority women. The proposal would authorize funding for research and education for fiscal years 2026–2031, but would not itself provide that money.
The Director of the National Institutes of Health (in this section referred to as the Director of NIH) shall expand, intensify, and coordinate programs for the conduct and support of research with respect to triple-negative breast cancer.
The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, shall develop and disseminate to the public information regarding triple-negative breast cancer
The Secretary of Health and Human Services, acting through the Administrator of the Health Resources and Services Administration, shall develop and disseminate to health care providers information on triple-negative breast cancer
Such information shall include the elevated risk for minority women to develop triple-negative breast cancer and the range of available options for the treatment of symptomatic triple-negative breast cancer.
For the purposes of carrying out this subsection, there are authorized to be appropriated such sums as may be necessary for each of the fiscal years 2026 through 2031.
Section 1 names the proposal the Triple-Negative Breast Cancer Research and Education Act of 2025.
This Act may be cited as the Triple-Negative Breast Cancer Research and Education Act of 2025.
The bill's findings describe triple-negative breast cancer as lacking estrogen and progesterone receptors and excess HER2 protein. They state that research does not adequately explain its frequency, treatment costs, or prevention and cure among minority women. These are the proposal's stated findings.
Triple-negative breast cancer is a term used to describe breast cancers whose cells do not have estrogen receptors and progesterone receptors, and do not have an excess of the HER2 protein on their sources.
Current research and available data do not provide adequate information on— (A) the rates of prevalence and incidence of triple-negative breast cancer in African-American, Hispanic, and other minority women; (B) the costs associated with treating triple-negative breast cancer; and (C) the methods by which triple-negative breast cancer may be prevented or cured in these women.
Section 3 would add a new section to the Public Health Service Act requiring the National Institutes of Health to expand, intensify, and coordinate research on triple-negative breast cancer.
Subpart I of part C of title IV of the Public Health Service Act (42 U.S.C. 285 et seq.) is amended by inserting after section 417A (42 U.S.C. 285a–7) the following: 417B. Triple-negative breast cancer
The Director of the National Institutes of Health (in this section referred to as the Director of NIH) shall expand, intensify, and coordinate programs for the conduct and support of research with respect to triple-negative breast cancer.
The National Institutes of Health would carry out the research through its appropriate institutes, offices, and centers, including the four named in the bill. The Office of Research on Women’s Health director would coordinate their activities.
The Director of NIH shall carry out this subsection through the appropriate institutes, offices, and centers of the National Institutes of Health, including the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Environmental Health Sciences, the Office of Research on Women’s Health, and the National Institute on Minority Health and Health Disparities.
The Director of the Office of Research on Women’s Health shall coordinate activities under this subsection among the institutes, offices, and centers of the National Institutes of Health.
The Department of Health and Human Services, through the Centers for Disease Control and Prevention, would have to develop and distribute public information. It would cover how often the cancer occurs among women, minority women's elevated risk, and medically appropriate treatment options for cancer that causes symptoms.
The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, shall develop and disseminate to the public information regarding triple-negative breast cancer, including information on— (A) the incidence and prevalence of triple-negative breast cancer among women; (B) the elevated risk for minority women to develop triple-negative breast cancer; and (C) the availability, as medically appropriate, of a range of treatment options for symptomatic triple-negative breast cancer.
The health secretary could distribute public information directly or arrange distribution through nonprofits, consumer groups, colleges and universities, government agencies, or the media.
The Secretary may disseminate information under paragraph (1) directly or through arrangements with nonprofit organizations, consumer groups, institutions of higher education, Federal, State, or local agencies, or the media.
Through the Health Resources and Services Administration, the health secretary would also have to develop and distribute information to keep health care providers informed. Required topics would include minority women's elevated risk and available treatments for triple-negative breast cancer that causes symptoms.
The Secretary of Health and Human Services, acting through the Administrator of the Health Resources and Services Administration, shall develop and disseminate to health care providers information on triple-negative breast cancer for the purpose of ensuring that health care providers remain informed about current information on triple-negative breast cancer. Such information shall include the elevated risk for minority women to develop triple-negative breast cancer and the range of available options for the treatment of symptomatic triple-negative breast cancer.
Each of the three programs—research, public education, and provider information—would receive authorization for whatever funding is necessary in fiscal years 2026–2031. An authorization permits future appropriations; it does not itself supply funding or set a dollar amount.
(4) Authorization of appropriations For the purposes of carrying out this subsection, there are authorized to be appropriated such sums as may be necessary for each of the fiscal years 2026 through 2031.
(3) Authorization of appropriations For the purpose of carrying out this subsection, there are authorized to be appropriated such sums as may be necessary for each of the fiscal years 2026 through 2031.
(2) Authorization of appropriations For the purpose of carrying out this subsection, there are authorized to be appropriated such sums as may be necessary for each of the fiscal years 2026 through 2031.
The proposed section defines minority women by reference to an existing statutory definition of racial and ethnic minority groups in section 1707(g).
In this section, the term minority women means women who are members of a racial and ethnic minority group, as defined in section 1707(g).
The supplied September 24, 2026 source snapshot records introduction in the House and referral to the House Committee on Energy and Commerce on March 3, 2025.
Source snapshot updated 2026-09-24T23:41:16Z. 2025-03-03: Referred to the House Committee on Energy and Commerce. 2025-03-03: Introduced in House
A closer look
Reviewed version: Introduced in House · 2025-03-03. These findings describe provisions and who may benefit; they are not judgments of waste, corruption, or motive.
This review covers the supplied bill text. “None identified” does not rule out provisions in later versions or accompanying reports and disclosures.
Provisions outside the bill’s main subject, or policy changes attached to appropriations.
None identified in the reviewed text
No unrelated provision or policy change attached to appropriations was identified in the complete supplied introduced text. This conclusion does not establish absence in other versions or accompanying materials.
Spending directed to particular recipients or places outside ordinary competitive or formula-based allocation.
None identified in the reviewed text
No congressionally directed spending for a particular recipient or place was identified in the complete supplied introduced text. This conclusion is limited to that version and does not establish formal earmark status or absence in accompanying materials.
Narrow exceptions, exemptions, or preferential treatment that warrant a closer look.
None identified in the reviewed text
No materially narrow carve-out, special exemption, or preferential treatment was identified in the complete supplied introduced text. A program's intended beneficiaries and routine administration alone do not qualify. This conclusion does not extend to other versions or accompanying materials.
Full text preserved for this analysis. Legislative record snapshot: Sep 24, 2026. How PlainBill uses AI